Updated time: 2021-02-25 11:00:12
The present invention discloses the selective inhibitors and other novel sialyltransferase inhibitors which are effective to selectively regulate (suppress) A 2,3- and A 2,6 N-linked glycans sialylated proteins (non O-linked glycans proteins). These selective sialyltransferase inhibitors were demonstrated to improve the water solubility properties, reduce toxicity, inhibit a variety of cancer cell migration and invasion, exhibit angiogenesis inhibition of human umbilical vein endothelial cell, and thereby to suppress tumor growth and metastasis.
- There is no selective sialyltransferase inhibitors present in the drug market and literature. This invention provides an alternative treatment option of molecular targeted therapy for cancer patients who have an overexpression of the "sialylated N- linked glycoproteins" profiling!
- The selective sialyltransferase inhibitors have a higher water solubility and lower toxicity than those of the conventional sialyltransferase inhibitors.
- The existing molecular targeted cancer therapies do not include this technology. This invention is novel.
- The selective sialyltransferase inhibitors have more effective therapeutic advantages (e.g., inhibition of tumor growth and delay of cancer metastasis) than those of the existing sialyltransferase inhibitors.
03A-1040522
US 10889611 B2、TW I618714
- Molecular targeted therapy for cancer
- Reduction of side effects for chemotherapy patients
- Inflammation treatment
- Crohns disease
Wen-Shan Li, Wen-Chun Hung, Chia-Ning Shen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Selective Sialyltransferase Inhibitors Suppress Cancer Growth and Metastasis